Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates and Tumor-Bearing Humanized Mice
Maura H. Parker(CTI BioPharma (United States)), Byoung Y. Ryu(CTI BioPharma (United States)), Ryan Larson(CTI BioPharma (United States)), Mollie M. McDonnell(University of Washington), Weiliang Tang(Chinese University of Hong Kong), Laurie Beitz(Seattle Children's Hospital), Don Parrilla(CTI BioPharma (United States)), Andrew M. Scharenberg(CTI BioPharma (Italy)), Chang‐Chih Wu(University of Tennessee Health Science Center), Sara J. Cooper, Kathryn Michels(CTI BioPharma (United States)), Justin Theophilus Ulrich-Lewis(CTI BioPharma (United States)), Susana Hernández, Seungjin Shin(Vector (United States)), Greyson Hamilton, Chris Nicolai, Anai M. Perez(Fred Hutch Cancer Center)
Cited by 7
Related Papers
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
|New England Journal of Medicine|2006|902
ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology
|Nature|2001|897